By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paced by accelerating sales of its OVA1 test, Vermillion today reported revenues in the fourth quarter rose 152 percent year over year.

For the period ended Dec. 31, 2011, total revenues were $868,000, up from $345,000 a year ago as product revenues, comprised of sales of the company's OVA1 ovarian cancer test, increased to $755,000 from $149,000 a year ago. Testing volume increased 40 percent year over year to 4,118, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.